Core C: Genomics and High Throughput Screening Core

该核心提供了尖端的工具，使研究人员能够监测正常造血过程中发生的细胞和分子变化，或与骨髓衰竭（BMF）、非恶性骨髓增生异常综合征或红细胞生成/巨核生成缺陷相关的病理状态，解决了该应用程序的三个重点，详见总体描述。显然，需要快速、高通量地识别和分析影响造血细胞向各种谱系发展的药物，并开发用于基质/生态位环境研究的小型化系统。戴蒙德博士是宾夕法尼亚大学（UPENN） PCMD的主任，他于2005年建立了PCMD作为核心设施。他在内皮生物学、血液生物学和血液系统生物学方面拥有20年的众多项目经验。他已经和dr。Poncz， French和Gadue研究成熟巨核细胞对血小板形成的生态位效应。他将担任SubCore C-1的总董事和董事。鲍德温博士将指导造血过程中细胞中RNA和DNA变化的分析。他在微阵列分析方面有11年的工业和学术经验，是美国国立卫生研究院神经科学微阵列联盟顾问小组的成员，是生物分子资源设施协会微阵列研究小组的联合主席，并定期与国家层面的核心主管进行互动（见BIOSKETCH）。鲍德温博士于2001年创立了宾夕法尼亚大学微阵列研究所，2005年被任命为分子诊断和基因分型研究所主任，并合并了两个实验室，创建了分子分析研究所。他曾与dr。Weiss, Blobel, Carroll, Diamond, Discher, Gewirtz， June和Pear对与P30直接相关的努力的研究。

This Core provides cutting edge tools that allow investigators to monitor cellular and molecular changes that occur during normal hematopoiesis or in pathological states associated with bone marrow failure (BMF), nonmalignant myelodysplastic syndromes or defects in erythropoiesis/megakaryopoiesis, addressing the three foci of this application as detailed in the OVERALL DESCRIPTION. There is a clear need for services to identify and analyze in a rapid, high throughput fashion drugs that influence hematopoietic cell commitment to various lineages and to develop miniaturized systems for studies of stromal/niche environments. Dr. Diamond is the director of the University of Pennsylvania (UPENN) PCMD, which he established as a Core Facility in 2005 (see BIOSKETCH). Dr. Diamond has 20 years of experience with numerous projects in endothelial biology, blood biology, and blood systems biology. He already has been working with Drs. Poncz, French and Gadue on niche effects on thrombopoiesis from mature megakaryocytes. He will be overall Director and Director of SubCore C-1. Dr. Baldwin will direct the analysis of RNA and DNA changes in cells during hematopoiesis. He has 11 years of industrial and academic experience in microarray assays, serves on the Neuroscience Microarray Consortium Advisory Panel for the NIH, co-chairs the MicroArray Research Group of the Association of Biomolecular Resource Facilities, and interacts regularly with core directors on a national level (see BIOSKETCH). Dr. Baldwin founded the Penn Microarray Facility in 2001, was appointed Director of the Molecular Diagnosis and Genotyping Facility in 2005, and has merged the two laboratories to create the Molecular Profiling Facility. He has conducted previous genomic profiling projects with Drs. Weiss, Blobel, Carroll, Diamond, Discher, Gewirtz, June and Pear on efforts directly relevant to this P30. We have combined components of the two UPENN cores run by Drs. Diamond and Baldwin to develop a single core for this P30 to incorporate state-of-the-art resources on our campus that will unite our abilities to analyze normal, pathologic and manipulated hematopoietic cells. SubCore C-1 offers high-throughput microscale screening for compounds that affect various aspects of hematopoietic cell biology, including lineage commitment (either from embryonic stem (ES) cells or more differentiated progenitors), survival, proliferation or maturation into mature blood cells. SubCore C-2 will analyze changes that occur in the RNA expression profiles and epigenetic DNA marks in these cells either de novo or after modifications using Core E. We believe that these two SubCores reflect a common theme of rapidly analyzing cells and cellular changes using complex methodologies with significant investment in rapidly changing equipment and technologies. Core C is committed to bringing the most current and innovative technologies to the P30 investigators, while providing campus-wide standardization of services to support cooperative efforts by different investigators with complementary interests and expertise. Our goal is to provide significant labor-intensive service and guidance at very competitive pricing, supported in part by efficiency of utilization and by UPENN financial support.